{
  "id": 12643433,
  "title": "BMO reiterates Trevi Therapeutics stock rating after rival study fails",
  "url": "https://urgent.news/2026/10/07/bmo-reiterates-trevi-therapeutics-stock-rating-after-rival-study-fails",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-07T14:24:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/bmo-reiterates-trevi-therapeutics-stock-rating-after-rival-study-fails-93CH-4937030"
  },
  "original_language": "en",
  "account": "BMO Capital has maintained an Outperform rating and a $36.00 price target on Trevi Therapeutics (NASDAQ:TRVI) shares, following a rival clinical trial failure. This rating mirrors Wall Street's bullish sentiment, with analysts generally endorsing a Strong Buy consensus and price targets spanning from $23 to $40. Currently, the stock is priced at $13.42, having slipped by approximately 8% over the past week. Trevi Therapeutics’ Phase 2b ASPIRE study, which tested the drug taplucainium for chronic cough, did not meet its primary endpoint as the drug proved to be ineffective in reducing cough frequency. This outcome weakens taplucainium's potential as a treatment option in the chronic cough market, as it lacked the efficacy expected from a once-daily inhaled competitor. Trevi Therapeutics is now focusing on its drug candidate Haduvio, which boasts unique central and peripheral activity, with pre-existing proof-of-concept data for chronic cough and IPF-related cough. The company plans to conduct a sample-size re-estimation for its LAKE study in Q4 2026, with further clinical readouts expected in the second half of 2027. While InvestingPro analysis suggests that Trevi Therapeutics' stock may be overvalued compared to its fair value estimate, independent research, such as the Pro Research Report, can provide further insights into the company's valuation and growth prospects.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}